V4b toric and V4c toric implantable collamer lens for myopic astigmatism: 6 month follow-up

Session Details

Session Title: Posterior chamber Phakic IOLS for correction of Myopia

Session Date/Time: Monday 15/09/2014 | 08:00-10:30

Paper Time: 08:24

Venue: Capital Hall B

First Author: : C.Lisa SPAIN

Co Author(s): :    B. Alfonso-Bartolozzi   L. Fernández-Vega Cueto   J. Alfonso        

Abstract Details

Purpose:

To assess the predictability, stability, safety and efficacy of the V4b toric and V4c toric Implantable Collamer lens (TICL) to correct moderate and high astigmatism.

Setting:

Instituto Oftalmológico Fernández-Vega. Oviedo. Spain.

Methods:

This study evaluated 35 eyes of 20 patients implanted with a TICL V4b and 32 eyes of 18 patients with a TICL V4c. In the V4b group, the mean sphere was -5.46 diopters (D) ± 4.17 (SD) (range -12 to +3 D) and the mean cylinder, -3.14 ± 1.19 D (range -6 to -1.50 D). In the V4c group, the mean sphere was -6.55 ± 2.96 D (range -12 to +3.25 D) and the mean cylinder was -2.99 ± 1.20 D (range -6 to -1.50 D). Uncorrected (UDVA) and corrected distance visual acuity (CDVA), refraction, TICL vault and adverse effects were evaluated over 6 months.

Results:

Refractive and visual outcomes with V4b and V4c TICLs are very similar. The mean sphere was -0.04 ± 0.16 D (range -0.75 to 0 D) with 97% of the eyes within ± 0.50 D of the target (r2=0.99) and -0.03 ± 0.09 D (range -0.25 to 0 D) with 85% of eyes within ± 0.50 D of the target (r2=0.99) for V4b and V4c. The mean cylinder was -0.29 ± 0.42 D (range -1 to 0 D) and -0.28 ± 0.54 D (range -1.50 to 0 D) with 65% and 73% of the eyes having less than 0.25 D of refractive cylinder, for V4b and V4c, respectively. The mean Snellen UDVA were 0.89 ± 0.16 and 0.94 ± 0.12; mean CDVA were 0.95 ± 0.12 and 0.99 ± 0.05 for V4b and V4c groups, respectively. For the V4b group, 77% had CDVA of 20/20, no eyes lost any line of CDVA and 43% of eyes gained 1 line or more. The safety index was 1.08 at 6 months. For V4c group, 93% had CDVA of 20/20, no eyes lost any line of CDVA and 60% of eyes gained 1 line or more. The safety index was 1.1 at 6 months.

Conclusions:

Visual and refractive outcomes were good, comparable and stable throughout the follow-up period with both TICL models evaluated; showing that these TICLs are predictable, stable, safe and effective to correct low and high levels of astigmatism. Furthermore, no intraoperative or postoperative complications were observed at 6 months follow-up with any TICL evaluated.

Financial Interest:

NONE